Skip to main content

Month: June 2020

Demant A/S: Opdatering vedrørende effekten af coronavirus

Opdatering vedrørende effekten af coronavirusForbedrede vilkår på høresundhedsmarkedet som følge af den gradvise genåbning af samfundKoncernens omsætnings-runrate (inkl. EPOS) ligger p.t. på 50-60 % af vores oprindelige forventningerForventninger til 2020 er fortsat trukket tilbage pga. usikkerhed om, hvor hurtigt vi vil se bedringI de seneste uger er de indførte restriktioner som følge af coronavirus blevet lempet i mange lande, deriblandt de vigtigste markeder for høresundhedsprodukter, og efterhånden som samfund gradvist åbner igen, er også mulighederne for at servicere brugerne blevet bedre. Forholdene på høresundhedsmarkedet er således blevet forbedret siden begyndelsen af maj, da vi offentliggjorde vores periodemeddelelse, men markedsforholdene varierer betydeligt fra land til land og fra det ene forretningsområde til det andet. De...

Continue reading

Valmet acquires 14.9% ownership in the future Neles

Valmet Oyj’s stock exchange release (inside information) on June 17, 2020 at 8:45 a.m. EETValmet has today agreed to acquire 22,374,869 shares in the future Neles Corporation from Solidium Oy, representing 14.88% of all Neles’ shares and votes. The transaction between Valmet and Solidium is expected to take place on July 1, 2020.Neles Corporation is planned to be created in the partial demerger of Metso, in which Metso’s Flow Control business would become the independent Neles Corporation and would continue Metso’s listing on Nasdaq Helsinki. The completion of the partial demerger is currently expected to take place on June 30, 2020 (pending final merger control approvals).After the partial demerger, Neles will be an independent globally leading diversified valve, valve automation and service company with net sales in 2019 amounting to...

Continue reading

Valmet hankkii 14,9 prosentin omistusosuuden tulevasta Neleksestä

Valmet Oyj:n pörssitiedote (sisäpiiritieto) 17.6.2020 klo 8.45Valmet on tänään sopinut ostavansa 22 374 869 osaketta tulevasta Neles Oyj:stä Solidium Oy:ltä. Tämä vastaa 14,88 % Neleksen kaikista osakkeista ja äänistä. Valmetin ja Solidiumin välisen kaupan odotetaan tapahtuvan 1. heinäkuuta 2020.Neles Oyj on tarkoitus luoda Metson osittaisjakautumisessa, jossa Metson Flow Control -liiketoiminnasta muodostuisi itsenäinen Neles Oyj jatkamaan Metson listausta Nasdaq Helsingissä. Tällä hetkellä osittaisjakautumisen odotetaan tapahtuvan 30. kesäkuuta 2020 (edellyttäen lopullista viranomaishyväksyntää).Osittaisjakautumisen jälkeen Neles tulee olemaan itsenäinen, globaalisti johtava venttiili-, venttiiliautomaatio- ja palveluyhtiö, jonka liikevaihto vuonna 2019 oli 660 miljoonaa euroa ja oikaistu EBITA-marginaali 14,6 %. Neleksen pääkonttori...

Continue reading

Ny koncernledning i SkiStar – Lars-Göran Dahl tillträder som fastighetsutvecklingsdirektör och lämnar därmed SkiStars styrelse

SkiStar gör förändringar i koncernledningen per den 1 september 2020 som ett led i bolagets arbete med att effektivisera driften av skidanläggningarna och förstärka fastighetsaffären. Två viktiga rekryteringar genomförs. Lars-Göran Dahl tillträder den 1 oktober 2020 som fastighetsutvecklingsdirektör i bolaget. Niclas Sjögren-Berg blir från och med den 1 september 2020 operationell direktör med ansvar för destinationsdrift på SkiStars samtliga destinationer. Samtidigt lämnar de fem destinationscheferna samt den tekniska direktören SkiStars koncernledning. Övriga befintliga koncernledningsmedlemmar kvarstår.Lars-Göran Dahl, född 1961, är styrelseledamot i SkiStar AB sedan årsstämman 2019 och arbetar sedan 2014 som fastighets- och transaktionschef på Diös. Lars-Göran är civilekonom och har tidigare bl.a. varit ansvarig för Riksbyggens kommersiella...

Continue reading

Kiadis to present at the Virtual European Biotech Investor Day 2020

Amsterdam, The Netherlands, June 17, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that Kiadis will present at the Virtual European Biotech Investor Day 2020 hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq on Thursday, June 25, 2020 at 1:30pm EDT.The presentation will be webcast live and may be accessed by visiting the “For Investors” section of the Company’s website under the “Events and Presentations” tab at https://www.kiadis.com/. A replay of the webcast will be available for 60 days.Date: Thursday, June 25, 2020Time: 1:30pm EDTWebcast: https://www.webcaster4.com/Webcast/Page/2408/35385Kiadis Contacts:Dutch Translation/Nederlandse vertalingKiadis Pharma nv (‘Kiadis’) (Euronext Amsterdam...

Continue reading

African Gold Group Announces Robust Definitive Feasibility Study for its 100,000 Ounce Per Year Kobada Gold Project With Renewable Energy Source

TORONTO, June 17, 2020 (GLOBE NEWSWIRE) — African Gold Group, Inc. (TSX-V: AGG) (“AGG” or the “Company”) is pleased to provide a National Instrument 43-101: Standards of Disclosure for Mineral Projects (“NI 43-101”) compliant updated mineral resource and reserve estimate and results of the definitive feasibility study (“DFS”) for the Company`s Kobada Gold Project (the “Kobada Gold Project”) located in southern Mali.  Highlights include:Average annual production of 100,000 ounces of gold per annum for the first 5 years of operation.Total gold production of 728,654 ounces over 9.4 years life of mine, based on current reserves.Average total operating cash costs US$704/oz for the Life of Mine (“LOM”).LOM All-In Sustaining Cost (“AISC”) of US$782/oz.Pre-tax NPV5% of US$283.9 million with an IRR of 45.5% and a post-tax NPV5% of $226 million...

Continue reading

Parkland Announces $400 Million Offering of Senior Unsecured Notes

(All financial figures are approximate and in Canadian dollars unless otherwise noted)NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATESCALGARY, Alberta, June 16, 2020 (GLOBE NEWSWIRE) — Parkland Corporation (“Parkland”, “we”, the “Company”, or “our”) (TSX:PKI), announced today that it has entered into an underwriting agreement to sell, pursuant to a private placement (the “Offering”), $400 million aggregate principal amount of 6.00% senior unsecured notes due 2028 at par (the “Notes”).Parkland intends to use the net proceeds from the Offering along with cash on hand to redeem all of the outstanding: (i) $200 million aggregate principal amount of 5.50% senior notes (the “5.50% Senior Notes”) with a final maturity date of May 28, 2021;...

Continue reading

Tiger Merger Sub Co. Extends Expiration Date to June 26, 2020 for Tender Offers and Consent Solicitations Relating to Tech Data Corporation’s 3.700% Senior Notes due 2022 and 4.950% Senior Notes due 2027

NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) — Tiger Merger Sub Co. (the “Offeror”), an affiliate of certain investment funds managed by affiliates of Apollo Global Management, Inc. (together with its consolidated subsidiaries, “Apollo”), announced today that it has further extended the Expiration Date (as defined in the Offer to Purchase (as defined below)) for the previously announced Tender Offers and Consent Solicitations (each as defined below) relating to Tech Data Corporation’s (i) 3.700% Senior Notes due 2022 (the “2022 Notes”) and (ii) 4.950% Senior Notes due 2027 (the “2027 Notes” and, together with the 2022 Notes, the “Notes”). The Expiration Date was previously extended to June 16, 2020. As a result of this further extension, the Expiration Date will now be 5:00 p.m., New York City time, on June 26, 2020 (unless further...

Continue reading

Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis

FDA approval for Cosentyx® is based on the Phase III PREVENT trial,  demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis (axSpA) disease spectrum There are an estimated 2.7M people living with axial spondyloarthritis (axSpA) in the US; however, it remains significantly underdiagnosed1,2 nr-axSpA approval is the fourth indication for Cosentyx, which is backed by five years of clinical data supporting long-term safety and efficacy across moderate to severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)3-8Basel, June 17, 2020 — Novartis, a leader in rheumatology and immuno-dermatology, today announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of active non-radiographic...

Continue reading

LGI Homes Expands Denver Footprint With the Opening of Two New Communities

DENVER, June 16, 2020 (GLOBE NEWSWIRE) — LGI Homes, Inc. (Nasdaq:LGIH) today announced the opening of two new communities, both north of downtown Denver. LGI Homes brings two unique product line offerings to the Denver area with community openings in Keenesburg and Mead. Both new construction neighborhoods showcase a lineup of affordable, quality-built homes that will attract Denver home shoppers at a time when interest rates are low and the demand for homeownership is high.Evans Place, located in the town of Keenesburg, offers three- and four-bedroom homes ranging in size from 1,293 to 2,363 square feet with prices starting in the low-$300s. These new homes include an incredible array of stylish features and energy-efficient upgrades found in LGI Homes’ CompleteHome™ package. From Wi-Fi-enabled garage door openers and programmable...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.